Core Viewpoint - Jianyou Co., Ltd. announced that its subsidiary, Meitheal Pharmaceuticals, Inc., received approval from the U.S. FDA for the production of Acetate Octreotide Injection in multiple concentrations [2] Group 1: Company Developments - Meitheal Pharmaceuticals, Inc. has been granted an approval letter by the U.S. FDA for the production of Acetate Octreotide Injection at concentrations of 50 mcg/mL, 100 mcg/mL, and 500 mcg/mL [2] - The approval allows production to take place at the facilities of Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. [2]

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 （六）申 请 人：Meitheal Pharmaceuticals Inc. 二、药品其他相关情况 关于子公司获得美国FDA醋酸奥曲肽注射液 药品增加生产场地注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）子公司 Meitheal Pharmaceuticals, Inc.（以下简称"Meitheal"）于近日收到美国食品药品 监督管理局（以下简称"美国 FDA"）签发的醋酸奥曲肽注射液，50 mcg/mL, 100 mcg/mL, 和 500 mcg/mL（ANDA 号：075957）增加生产场地的批准信，批准在 南京健友生化制药股份有限公司场地生产，现将相关情况公告如下： 一、药品的基本情况 （一）药品名称：醋酸奥曲肽注射液 ...

特此公告。 南京健友生化制药股份有限公司董事会 南京健友生化制药股份有限公司 关于选举第五届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京健友生化制药股份有限公司（以下简称"公司"）于 2025 年 11 月 12 日召开 2025 年第一次临时股东大会，审议通过了《关于变更注册资本、取消监 事会并修订公司章程的议案》，根据修订后的《公司章程》，公司董事会成员中 应当包括 1 名职工代表董事，由公司职工通过职工代表大会民主选举产生。 根据《公司法》《上市公司章程指引》《上海证券交易所股票上市规则》等 法律法规和规范性文件以及《公司章程》的相关规定，公司于 2025 年 11 月 12 日召开了职工代表大会，经全体与会职工代表表决，选举黄锡伟先生为公司第五 届董事会职工代表董事（简历详见附件），黄锡伟先生原为第五届董事会非职工 董事（同时为第五届董事会战略委员会成员），本次选举完成后，黄锡伟先生变 更为职工代表董事，公司第五届董事会成员及各专门委员会成员不变。黄锡伟先 生任期自本次职工代表大 ...

本律师同意将本法律意见书随贵公司本次股东大会决议一并公告,并依法 对本法律意见书承担相应的责任。 本律师根据相关法律、法规和规范性文件的要求,按照律师行业公认的业 务标准、道德规范和勤勉尽责精神,出具法律意见如下: 一、关于本次股东大会的召集、召开程序和召集人资格 1.本次股东大会由董事会召集。2025年10月24日,贵公司召开第五届董 事会第十五次会议,决定于 2025年11月 12日召开 2025年第一次临时股东大 会。2025年10月25日,贵公司在《中国证券报》《上海证券报》及上海证券 交易所网站(www.sse.com.cn)上刊登了该次董事会决议和《关于召开 2025 年 第一次临时股东大会的通知》（以下简称"会议通知"）。 江苏世纪同仁律师事务所关于 南京健友生化制药股份有限公司2025年第一次临时股东大会的 法律意见书 致:南京健友生化制药股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》和中国证监会 《上市公司股东会规则》等法律、法规和规范性文件以及贵公司《章程》的规 定,本所受贵公司董事会的委托,指派本律师出席贵公司 2025年第一次临时股 东大会,并就本次股东大会的召集、 ...

证券代码：603707 证券简称：健友股份 公告编号：2025-084 南京健友生化制药股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 11 月 12 日 (二)股东大会召开的地点：南京市高新技术开发区学府路 16 号南京健友生化制 药股份有限公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 326 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 1,185,561,288 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 73.3805 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，由董事长唐咏群先生主持，采用现场投票和 网络投票相结合的方式进行表决 ...

Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), announced that its subsidiary, Meitheal Pharmaceuticals, Inc., received approval from the U.S. Food and Drug Administration (FDA) to increase production sites for Acetate Octreotide Injection in various concentrations, which is expected to positively impact the company's operational performance [1] Group 1 - Meitheal Pharmaceuticals, Inc. received FDA approval for Acetate Octreotide Injection in concentrations of 50 mcg/mL, 100 mcg/mL, and 500 mcg/mL [1] - The approval includes the production site located at Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. [1] - The newly approved product is scheduled for market launch in the U.S. [1]

Core Viewpoint - The company Meitheal Pharmaceuticals, Inc., a subsidiary of Jianyou Co., Ltd. (603707.SH), has received approval from the U.S. FDA to increase production capacity for its Acetate Octreotide Injection at its Nanjing facility, which is significant for treating various medical conditions [1]. Group 1 - Meitheal Pharmaceuticals has been granted approval for Acetate Octreotide Injection in three concentrations: 50 mcg/mL, 100 mcg/mL, and 500 mcg/mL [1]. - The approved indications for the drug include treatment for acromegaly, severe diarrhea associated with metastatic carcinoid syndrome, flushing episodes, and diarrhea related to vasoactive intestinal peptide-secreting tumors [1].

Core Viewpoint - The company announced that its subsidiary, Meitheal Pharmaceuticals, Inc., received approval from the U.S. FDA for the production of Acetate Octreotide Injection in various concentrations, which is expected to positively impact the company's financial performance [1] Group 1 - The FDA approval includes the production of Acetate Octreotide Injection at concentrations of 50 mcg/mL, 100 mcg/mL, and 500 mcg/mL [1] - The approved product will soon be launched in the U.S. market [1] - The production will take place at the Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. facility [1]

Group 1: Non-Metallic Building Materials - The building materials industry shows signs of structural growth that gradually outweigh environmental impacts, with Q3 2025 reports indicating a recovery in revenue and profitability for several companies [2][25] - The cement sector continues to perform well overseas, particularly in Africa, while domestic demand and prices have weakened, suggesting a potential bottoming out in 2024 [4][26] - In the consumer building materials sector, revenue growth disparities among sub-industries are widening, driven by the impacts of real estate and local debt [5][27] Group 2: Biopharmaceuticals - Huadong Medicine's industrial segment maintains steady growth, with Q3 2025 revenue of 37.28 billion yuan, up 14.95% year-on-year, and net profit of 8.94 billion yuan, up 18.43% [7][8] - The medical aesthetics business faces short-term pressure due to economic factors, with a decline in revenue for both domestic and overseas operations [8] - The company is advancing its innovative pipeline, with several clinical trials ongoing for various cancer treatments [9][33] Group 3: Power Equipment and New Energy - Haibo Sichuang, a leader in energy storage, is expected to benefit from high industry demand, with Q3 2025 revenue reaching 3.39 billion yuan, a year-on-year increase of 124.4% [10][11] - The company's profitability has improved significantly, with a gross margin of 18.64% and a net margin of 9.05% in Q3 2025 [11] - The global energy storage market is projected to grow by 40%-50% in 2026, with significant contributions from both domestic and international markets [13] Group 4: Financial Engineering - The report highlights various asset allocation strategies, with the macro-factor-based strategy yielding a return of 4.23% in 2025, outperforming other strategies [14][15] - The performance of domestic asset strategies shows a positive trend, with October returns indicating a stable investment environment [15][16] - The overall economic outlook remains cautious, with manufacturing PMI indicating a contraction, while service sector activity shows slight improvement [16]

Core Viewpoint - The company, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., announced that its subsidiary, Meitheal Pharmaceuticals, Inc., received approval from the U.S. FDA to increase the production site for injectable vecuronium bromide, which is expected to positively impact the company's operating performance [1][4]. Group 1: Drug Information - The drug approved is injectable vecuronium bromide, indicated as an adjunct for general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation [1]. - The approved specifications for the drug are 10 mg/vial and 20 mg/vial, with ANDA number 074688 [1][5]. - The reference formulation of injectable vecuronium bromide is held by ORGANON USA INC under the brand name NORCURON, which was approved by the FDA in 1984 and 1992 [2]. Group 2: Financial and Developmental Aspects - The company has invested approximately RMB 2.4238 million in the research and development of injectable vecuronium bromide [3]. - The newly approved product is expected to be launched in the U.S. market soon, which may have a positive effect on the company's financial performance [4]. Group 3: Market Context - Currently, besides the original manufacturer, there are eight other companies in the U.S. that have received approval to market injectable vecuronium bromide in the same specifications [2].